Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABT Abbott Laboratories	$131.19 +0.7%	$131.34	$110.33 ▼ $141.23	$228.34B	0.7	6.87 million shs	4.84 million shs
DXCM DexCom	$80.90 +0.1%	$82.88	$57.52 ▼ $93.25	$31.72B	1.43	3.88 million shs	2.26 million shs
ISRG Intuitive Surgical	$479.20 -0.4%	$507.85	$425.00 ▼ $616.00	$171.78B	1.59	1.99 million shs	1.88 million shs
MDT Medtronic	$89.92 -3.1%	$89.43	$79.29 ▼ $96.25	$115.26B	0.8	7.73 million shs	19.17 million shs

7 Stocks to Ride The A.I. Megaboom

We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABT Abbott Laboratories	-1.02%	-0.81%	+5.26%	-3.60%	+17.41%
DXCM DexCom	-0.16%	+3.82%	-3.66%	-7.47%	+8.27%
ISRG Intuitive Surgical	+0.21%	+2.00%	-7.20%	-13.62%	+0.48%
MDT Medtronic	-0.26%	-0.07%	+3.46%	+7.59%	+9.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABT Abbott Laboratories	4.9723 of 5 stars	3.5	4.0	4.2	4.5	2.5	2.5	2.5
DXCM DexCom	4.8297 of 5 stars	3.5	4.0	0.0	4.7	3.5	2.5	1.9
ISRG Intuitive Surgical	4.7112 of 5 stars	3.3	3.0	0.0	4.0	4.2	2.5	1.9
MDT Medtronic	4.8177 of 5 stars	2.3	5.0	3.3	4.1	4.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABT Abbott Laboratories	2.91	Moderate Buy	$144.47	10.12% Upside
DXCM DexCom	2.95	Moderate Buy	$99.89	23.48% Upside
ISRG Intuitive Surgical	2.63	Moderate Buy	$595.95	24.36% Upside
MDT Medtronic	2.59	Moderate Buy	$98.19	9.20% Upside

Current Analyst Ratings Breakdown

Latest MDT, DXCM, ISRG, and ABT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	ISRG Intuitive Surgical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$615.00
8/14/2025	MDT Medtronic	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/1/2025	DXCM DexCom	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$106.00
7/31/2025	DXCM DexCom	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/31/2025	DXCM DexCom	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
7/31/2025	DXCM DexCom	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$99.00 ➝ $102.00
7/31/2025	DXCM DexCom	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$95.00 ➝ $102.00
7/31/2025	DXCM DexCom	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$105.00 ➝ $106.00
7/30/2025	DXCM DexCom	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$93.00 ➝ $98.00
7/23/2025	ISRG Intuitive Surgical	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$547.00 ➝ $585.00
7/23/2025	ISRG Intuitive Surgical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$575.00 ➝ $595.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABT Abbott Laboratories	$41.95B	5.44	$6.56 per share	20.01	$27.62 per share	4.75
DXCM DexCom	$4.03B	7.87	$2.25 per share	36.02	$5.38 per share	15.04
ISRG Intuitive Surgical	$8.35B	20.57	$7.97 per share	60.12	$46.41 per share	10.33
MDT Medtronic	$33.54B	3.44	$7.49 per share	12.00	$37.62 per share	2.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABT Abbott Laboratories	$13.40B	$7.98	16.44	22.90	2.50	32.43%	18.32%	10.71%	10/15/2025 (Estimated)
DXCM DexCom	$576.20M	$1.44	56.18	32.89	1.70	13.29%	30.41%	10.08%	10/23/2025 (Estimated)
ISRG Intuitive Surgical	$2.32B	$7.17	66.83	62.80	5.03	28.51%	14.56%	12.93%	10/16/2025 (Estimated)
MDT Medtronic	$4.66B	$3.62	24.84	15.42	2.42	13.90%	14.54%	7.83%	8/19/2025 (Estimated)

Latest MDT, DXCM, ISRG, and ABT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q1 2026	MDT Medtronic	$1.23	$1.26	+$0.03	$0.81	$8.37 billion	$8.58 billion
7/30/2025	Q2 2025	DXCM DexCom	$0.45	$0.48	+$0.03	$0.45	$1.13 billion	$1.16 billion
7/22/2025	Q2 2025	ISRG Intuitive Surgical	$1.93	$2.19	+$0.26	$1.81	$2.35 billion	$2.44 billion
7/17/2025	Q2 2025	ABT Abbott Laboratories	$1.26	$1.26	N/A	$1.01	$11.01 billion	$11.14 billion
5/21/2025	Q4 2025	MDT Medtronic	$1.58	$1.62	+$0.04	$0.82	$8.81 billion	$8.93 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABT Abbott Laboratories	$2.36	1.80%	N/A	29.57%	54 Years
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
ISRG Intuitive Surgical	N/A	N/A	N/A	N/A	N/A
MDT Medtronic	$2.84	3.16%	N/A	78.45%	49 Years

Latest MDT, DXCM, ISRG, and ABT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/15/2025	MDT Medtronic	quarterly	$0.71	3.1%	9/26/2025	9/26/2025	10/17/2025
6/13/2025	ABT Abbott Laboratories	quarterly	$0.59	1.73%	7/15/2025	7/15/2025	8/15/2025
5/21/2025	MDT Medtronic	quarterly	$0.71	3.3%	6/27/2025	6/27/2025	7/11/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABT Abbott Laboratories	0.25	1.82	1.30
DXCM DexCom	0.48	1.52	1.35
ISRG Intuitive Surgical	N/A	5.17	4.18
MDT Medtronic	0.53	1.85	1.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABT Abbott Laboratories	75.18%
DXCM DexCom	97.75%
ISRG Intuitive Surgical	83.64%
MDT Medtronic	82.06%

Insider Ownership

Company	Insider Ownership
ABT Abbott Laboratories	0.46%
DXCM DexCom	0.32%
ISRG Intuitive Surgical	0.70%
MDT Medtronic	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABT Abbott Laboratories	114,000	1.74 billion	1.73 billion	Optionable
DXCM DexCom	10,300	392.15 million	390.90 million	Optionable
ISRG Intuitive Surgical	15,638	358.48 million	355.97 million	Optionable
MDT Medtronic	95,000	1.28 billion	1.28 billion	Optionable

MDT, DXCM, ISRG, and ABT Headlines

Recent News About These Companies

Why Medtronic Stock Dropped Today

3 hours ago | fool.com

Medtronic’s Mixed Performance and Strategic Uncertainty Lead to Hold Rating

5 hours ago | tipranks.com

Medtronic’s Modest Beat and Strategic Changes: Analyst Maintains Hold Rating Amid Growth Concerns

5 hours ago | tipranks.com

Nasdaq Down Over 300 Points; Medtronic Posts Upbeat Earnings

August 19 at 1:33 PM | benzinga.com

Can An Activist Shake Up Medtronic's 'More Solid Than Stellar' Results?

August 19 at 1:32 PM | investors.com

Medtronic PLC (MDT) Expands Community Health Program to Tackle Health Disparities | MDT stock news

August 19 at 1:32 PM | gurufocus.com

Medtronic Lifts Outlook as Revenue Jumps

August 19 at 1:10 PM | fool.com

From Home Visits to Health Victories: Global Health Tech Gets Personal

August 19 at 12:11 PM | gurufocus.com

Medtronic (MDT) Raises Full-Year EPS Guidance on Strong Q1 Performance

August 19 at 12:11 PM | gurufocus.com

Medtronic plc (MDT) Q1 2026 Earnings Call Transcript

August 19 at 12:11 PM | seekingalpha.com

Activist investor Elliott push spurs changes at Medtronic

August 19 at 12:11 PM | youtube.comY

Medtronic: The Opportunity Gets Healthier for Income Investors

...

August 19 at 11:40 AM | marketbeat.com

Medtronic (MDT) Shares Fall Amid Strategic Changes and Strong Q1 Earnings

August 19 at 11:31 AM | gurufocus.com

MDT Stock Falls Despite Q1 Earnings & Revenue Beat, FY26 EPS View Up

August 19 at 10:51 AM | zacks.com

Medtronic (MDT) is a Top-Ranked Growth Stock: Should You Buy?

August 19 at 10:46 AM | zacks.com

Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics

August 19 at 10:31 AM | zacks.com

Medtronic Posts 7 Percent Growth in Q1

August 19 at 9:10 AM | fool.com

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway.

August 19 at 9:10 AM | barrons.com

Medtronic (MDT) Q1 Earnings and Revenues Top Estimates

August 19 at 8:56 AM | zacks.com

Medtronic (MDT) Raises Full-Year Earnings Forecast Following Strong Q1

August 19 at 8:11 AM | gurufocus.com

Medtronic (MDT) Surpasses Earnings and Revenue Expectations

August 19 at 8:11 AM | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MDT, DXCM, ISRG, and ABT Company Descriptions

Abbott Laboratories NYSE:ABT

$131.19 +0.92 (+0.71%)

Closing price 03:59 PM Eastern

Extended Trading

$131.88 +0.68 (+0.52%)

As of 07:08 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

DexCom NASDAQ:DXCM

$80.90 +0.08 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$80.93 +0.03 (+0.04%)

As of 07:10 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Intuitive Surgical NASDAQ:ISRG

$479.20 -2.08 (-0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$481.00 +1.80 (+0.38%)

As of 07:14 PM Eastern

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. It has a collaboration agreement with FluoGuide A/S for head & neck cancer. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.

Medtronic NYSE:MDT

$89.92 -2.89 (-3.12%)

Closing price 03:59 PM Eastern

Extended Trading

$89.97 +0.05 (+0.06%)

As of 07:07 PM Eastern

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time